Total Count 123

JAMJOOM PHARMA - Latest News

16/10/2025
Jamjoom Pharma to announce Q3 2025 results on Oct. 23
Argaam
10/08/2025
Rundown of Jamjoom Pharma's financials, operating segments in Q2 2025
Argaam Special
06/08/2025
Jamjoom Pharma Q2 2025 results in line with estimates: GIB Capital
Argaam
27/07/2025
Jamjoom Pharma posts in-line Q2 2025 results, rating unchanged: AlJazira Capital
Argaam
27/07/2025
Jamjoom Pharma reviews 2025-2027 guidance
Argaam Special
24/07/2025
Jamjoom Pharma ups profit margin forecast to 33%: CEO
Argaam Special
24/07/2025
Jamjoom Pharma to distribute 20% dividend for H1 2025
Argaam
15/07/2025
Jamjoom Pharma plans to release Q2 2025 financials on July 24
Argaam
14/07/2025
Morgan Stanley 'market maker' for 40 TASI, Nomu firms
Argaam
07/07/2025
GIB Capital issues Q2 2025 earnings forecasts for Saudi companies
Argaam
06/07/2025
Q2 2025 earnings preview: AlJazira Capital
Argaam Special
06/07/2025
United Securities issues Q2 2025 earnings forecast
Argaam
03/07/2025
Al Rajhi Capital issues earnings estimates for Q2 2025
Argaam
01/07/2025
Jamjoom Pharma reappoints Mahmoud Jamjoom as Chairman
Argaam
26/06/2025
Jamjoom Pharma shareholders reject LTIP, buyback plan
Argaam
26/05/2025
Ranked: Tadawul's 50 most profitable companies in Q1 2025
Argaam Special
14/05/2025
How did analysts view Jamjoom Pharma Q1 2025 financials?
Argaam Special
14/05/2025
Jamjoom Pharma board proposes 100,000 share buyback
Argaam
12/05/2025
Jamjoom Pharma provides SAR 16.6M guarantee for Algeria JV loan
Argaam
05/05/2025
Ubhar Capital: Jamjoom Pharma Q1 profit above estimates, TP unchanged
Argaam
01/05/2025
Jamjoom Pharma’s profit grows on focus on high-margin therapeutic segments
Argaam Special
30/04/2025
Jamjoom Pharma revises guidance for next 3 years 
Argaam Special
29/04/2025
AlJazira Capital initiates coverage on Saudi pharmaceuticals sector, sets ratings
Argaam
21/04/2025
Highest-paid executives, board members of Saudi-listed firms in 2024
Argaam Special
20/04/2025
Jamjoom Pharma to disclose Q1 2025 results on April 30
Argaam
14/04/2025
Al Rajhi Capital issues Q1 2025 profit forecasts for TASI-listed firms
Argaam
14/04/2025
GIB Capital issues Q1 2025 earnings estimates
Argaam
10/04/2025
SNB Capital sets Q1 2025 earnings estimates
Argaam
06/04/2025
United Securities issues Q1 2025 earnings forecast
Argaam Special
08/03/2025
Al Rajhi Capital sets Jamjoom Pharma rating, TP
Argaam
06/03/2025
Jamjoom Pharma sales rise 19% in Saudi Arabia, eyes expansion: CEO
Argaam Special
26/02/2025
Jamjoom Pharma 2024 revenue growth reflects operational improvements: CEO
Argaam
25/02/2025
Jamjoom Pharma to distribute 14.6% dividend for H2 2024
Argaam
11/02/2025
Jamjoom Pharma provides SAR 27.1M guarantee to JV in Algeria
Argaam
02/02/2025
Jamjoom Pharma provides SAR 17.7M guarantee for Algeria joint venture
Argaam
30/01/2025
Jamjoom Pharma Q4 2024: What are analysts predicting?
Argaam Special
25/01/2025
Ubhar Capital initiates coverage of Jamjoom Pharma, sets rating, TP
Argaam
12/01/2025
SNB Capital sets Q4 2024 earnings estimates
Argaam Special
12/01/2025
Osool & Bakheet previews Q4 2024 earnings estimates
Argaam Special
09/01/2025
United Securities issues Q4 2024 earnings forecasts
Argaam
06/01/2025
GIB Capital issues Q4 2024 earnings estimates
Argaam
02/01/2025
Al Rajhi Capital issues Q4 2024 profit forecasts for TASI-listed firms
Argaam Special
01/01/2025
SNB Capital forecasts Tadawul earnings to rise 8% in 2025
Argaam
23/12/2024
Analyst ratings, average TP for Jamjoom Pharma post-Q3 2024
Argaam Special
27/10/2024
Jamjoom Pharma maintains 2024 guidance
Argaam Special
24/10/2024
What do analysts expect from Jamjoom Pharma's Q3 2024 results?
Argaam Special
10/10/2024
Jamjoom Pharma plans to disclose Q3 2024 financials on Oct. 27
Argaam
10/10/2024
GIB Capital's forecast on Q3 2024 earnings
Argaam Special
08/10/2024
Osool & Bakheet previews Q3 2024 earnings estimates
Argaam Special
07/10/2024
Al Rajhi Capital issues Q3 2024 earnings forecasts for more Tadawul-listed firms
Argaam

Popular Links

Quick Links

Join Us

Argaam.com Copyright © 2025, Argaam Investment, All Rights Reserved
Call Request